France's OTC Market in 2018: Self-Medication Sales Slump, Sanofi Claims Number-One Spot
Executive Summary
France's self-medication market had a difficult 2018, due to a weak flu season and changing dynamics in the sector, according to industry association Afipa. Despite this it was a good year for Sanofi, which overtook Boiron as the number-one OTC firm in the market, while its Doliprane analgesic became France's best-selling brand.
You may also be interested in...
French OTC Industry Warns Over-Regulation Is Threatening Its Future
Plans to move ibuprofen, aspirin and paracetamol OTCs behind the counter in French pharmacies will harm the country's self-medication industry, which is already lagging behind its European neighbors, warns local association Afipa.
France's Supplement Market in 2018: Demand For Probiotics and Natural Alternatives Drives Sales Growth
France's food supplements market enjoyed broad-based growth across key categories in 2018, driven by consumer demand for natural alternatives to conventional medicine. Over the 12 months, Pileje overtook Arkopharma as the dominant player in market, as its leading probiotics brand, Symbiosys, flew off the shelves.
France's Supplement Market in 2018: Demand For Probiotics and Natural Alternatives Drives Sales Growth
France's food supplements market enjoyed broad-based growth across key categories in 2018, driven by consumer demand for natural alternatives to conventional medicine. Over the 12 months, Pileje overtook Arkopharma as the dominant player in market, as its leading probiotics brand, Symbiosys, flew off the shelves.